Neil Littlejohn

Founder & Executive Director

Neil’s career has been shaped through over 20 years of extensive experience across multiple sectors and disciplines.

His experience in leading high performing teams has ranged from completing financial audits and delivering digitisation initiatives for healthcare practitioners, to delivering complex business restructuring programs within major Life Sciences corporations.

A Founding Director at Helixr, Neil has a hunger and passion for driving progress within the Life Sciences sector. Heading up Business Development at Helixr, he thrives on flexing his visionary and conceptual ability to help craft strategies with realistic and tangible outcomes.

Known for making complex things simple, Neil’s motivation and guiding mantra is his resolution and commitment to solving the problems of others. He strongly believes that through collaboration and cohesion, a team can achieve more than the sum of its parts, to the benefit of the whole organisation.

Written articles

Covid-19Life Sciences
June 18, 2021

COVID-19 and the Future of Life Sciences

Long-lasting effects of the pandemic may shape the future of the life sciences industry; companies will need to adapt over the short to long term.
Business RestructuringGlobal Tax Technologies
December 27, 2020

Brexit impacts on Life Sciences companies

After over forty years of membership, on 26th June 2016, the UK voted to leave the European Union (EU) through a referendum; three and a half years later the “split”…
Business Restructuring
December 26, 2020

Mergers, Acquisitions & Divestitures – What We Can Learn From Medicine

Business restructuring (mergers, acquisitions and divestures) face same similar challenges to those in medicine and the skills and behaviours demonstrated can be leveraged to drive success of these transactions.
Covid-19ERP Services
December 20, 2020

COVID-19 impact on ERP Delivery

As the globe is still combatting the COVID-19 pandemic, this insight focuses on how current ERP deployments have been impacted and how this could frame the “new-normal” post-COVID.